Objective: In this study, we aimed to report the effectiveness of hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and GATMO scores in predicting overall survival (OS) who underwent autologous stem cell transplantation (ASCT). Material and methods: The data of 263 MM and 204 lymphoma patients who underwent ASCT in the last 11 years were retrospectively analyzed. Results: Neutrophil engraftment time, thrombocyte engraftment time and collected CD34+ cell counts were similar in MM patients with HCT-CI 2 (all p 2 tended to be higher than those with HCT-CI 2 was 51.5 months, the estimated median OS of patients with HCT-CI 2 was 9.5 months (p=0.012). When lymphoma patients were divided into four groups according to their GATMO scores, the OS of the four groups was found to be different from each other (p<0.001). Conclusion: HCT-CI and GATMO scores predict OS in lymphoma patients but not MM patients.
C1 [Sarici, Ahmet; Erkurt, Mehmet Ali; Kuku, Irfan; Bicim, Soykan; Kaya, Emin; Berber, Ilhami; Ozgul, Mustafa] Inonu Univ, Turgut Ozal Med Ctr, Adult Hematol Dept, Malatya, Turkey.
[Bahcecioglu, Omer Faruk; Gok, Selim] Inonu Univ, Fac Pharm, Dept Clin Pharm, Malatya, Turkey.
[Keser, Muhammed Furkan] Inonu Univ, Turgut Ozal Med Ctr, Dept Internal Med, Malatya, Turkey.